Moolec Science stock is showing exceptional strength. What’s behind MLEC gains?GLASO Results Drive Investor Focus On MLEC StockThe program produced oil with about 45% gamma-linolenic acid after standard U.S. crushing, which the company says is among the highest levels reported at commercial scale.Moolec cultivated about 1,100 acres of engineered safflower in its 2025 campaign, with average yields near 2,200 pounds per acre, a 57% year-over-year increase from roughly 1,400 pounds per acre in 2024. Management ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - Smart Logistics Global Limited (SLGB) is up 198% at $3.67 [3] - Brand Engagement Network, Inc. (BNAI) is up 67% at $10.29 [3] - Boxlight Corporation (BOXL) is up 56% at $1.96 [3] - Moolec Science SA (MLEC) is up 51% at $6.64 [3] - Anteris Technologies Global Corp. (AVR) is up 15% at $6.63 [3] - Hycroft Mining Holding Corporation (HYMC) is up 10% at $47.20 [3] - Nathan's Famous, Inc. (NATH) is up 8% at $100.94 [3] - Progress Software Corporation (PRGS) is up 6% at $41.05 [3] - LightPath Technologies, Inc. (LPTH) is up 5% at $14.81 [3] - ZenaTech, Inc. (ZENA) is up 5% at $4.33 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) is down 29% at $3.81 [4] - Solo Brands, Inc. (SBDS) is down 21% at $5.25 [4] - GlucoTrack, Inc. (GCTK) is down 19% at $3.07 [4] - Galaxy Payroll Group Limited (GLXG) is down 19% at $2.26 [4] - INVO Fertility, Inc. (IVF) is down 13% at $2.04 [4] - Black Titan Corporation (BTTC) is down 11% at $2.11 [4] - Envirotech Vehicles, Inc. (EVTV) is down 10% at $3.30 [4] - Erasca, Inc. (ERAS) is down 6% at $9.21 [4] - ENDRA Life Sciences Inc. (NDRA) is down 6% at $4.31 [4] - Bonk, Inc. (BNKK) is down 6% at $3.74 [4]

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Company Highlights - Ambitions Enterprise Management Co. L.L.C (NASDAQ:AHMA) saw its stock price rise to $28.03, marking an 80.88% increase, driven by strong performance in the MICE and tourism sectors [1][7] - authID Inc. (NASDAQ:AUID) experienced a stock price increase to $1.77, a 78.34% rise, reflecting the growing demand for secure, biometric identity verification solutions [2][7] - CALLAN JMB INC. (NASDAQ:CJMB) saw its stock price surge to $3.91, a 249.12% increase, as it shifts towards cold-chain infrastructure to support the $100 billion GLP-1 pharmaceutical market [3][7] - Moolec Science S.A. (NASDAQ:MLEC) experienced a 101.42% increase in its stock price to $7.11, indicating market interest in alternative protein sources and sustainable food technologies [4] - Springview Holdings Ltd (NASDAQ:SPHL) saw its stock price jump to $15.9, a staggering 606.67% increase, highlighting robust demand in the construction sector [5] Industry Trends - The movements in stock prices reflect diverse sectors experiencing growth, including technology, biotechnology, logistics, and construction, indicating broader economic trends and investor interests [6] - Strategic initiatives and partnerships by these companies demonstrate a proactive approach to capitalizing on market opportunities and addressing industry demands [6]

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Core Insights - Moolec Science SA executed a reverse stock split at a 15-for-1 ratio on January 5, 2026, consolidating every 15 ordinary shares into one [1][5] - The total number of issued and outstanding ordinary shares decreased from approximately 10.9 million to about 726,118 shares [2] - The par value of each share was adjusted from $0.10 to $1.50, with the current stock price at $4.30, reflecting a 3.86% increase [3][5] - MLEC's stock has shown significant volatility over the past year, with a high of $157.05 and a low of $3.08, and the market capitalization is approximately $3.12 million [4][5] - The reverse stock split aims to stabilize the stock's performance and enhance its market perception [4][5]

Group 1 - The company Moolec Science SA has completed a share consolidation at a ratio of 15-for-1, effective January 5, 2026 [1] - Following the consolidation, shareholders will hold 1 ordinary share of par value US$1.50 for every 15 ordinary shares of par value US$0.10 each they previously held [1] - The share consolidation was approved during an extraordinary general meeting of shareholders on December 16, 2025, and by the company's board of directors on December 19, 2025 [1]

Core Viewpoint - Moolec Science SA has announced a share consolidation with a final ratio of 15-for-1, effective January 5, 2026, to comply with Nasdaq listing requirements [1][4]. Share Consolidation Details - The share consolidation will reduce the number of issued and outstanding ordinary shares from 10,891,761 to approximately 726,118 shares [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share, ensuring no dilutive effect on shareholders [3]. Compliance and Trading Information - The consolidation aims to regain compliance with Nasdaq's minimum bid price requirement of U.S.$1.00 per share, as per Nasdaq Listing Rule 5550(a)(2) [4]. - The new shares will be admitted to trading on the Nasdaq Capital Market under CUSIP number G6223S 125 starting January 5, 2026 [4]. Company Overview - Moolec Science is focused on producing animal proteins and nutritional oils in plants, utilizing molecular farming and precision fermentation [6]. - The company has a diversified pipeline that includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture [6]. - Moolec holds over 118 granted and pending patents across multiple technology platforms, indicating a strong intellectual property portfolio [6].

Financial Viability and Risks - The company faces substantial doubt about its ability to continue as a going concern, as indicated in its financial statements for the year ended June 30, 2025[111]. - The company has a history of losses and may not achieve or maintain profitability, which increases investment risk[111]. - The company may require additional financing to achieve its goals, and failure to secure necessary capital could delay or limit operations[111]. - As of June 30, 2025, the company reported a working capital deficit of $204.9 million, raising substantial doubt about its ability to continue as a going concern[122]. - The net losses for the year ended June 30, 2025, were $154.6 million, with an accumulated deficit of $57.3 million[123]. - The company had $248.0 million in total indebtedness as of June 30, 2025, with 92% classified as current[134]. - Bioceres S.A. defaulted on a portion of its financial debt amounting to $36.4 million in June 2025, initiating a debt restructuring process[141]. - Bioceres LLC received a notice of default on its financial debt of $69.5 million, leading to the auction of pledged BIOX shares[141]. - The company may need to secure additional capital to fund its longer-term capital and liquidity needs, as it does not expect to rely solely on cash balances and operating cash flow[123]. Competitive Landscape - The company operates in a highly competitive environment, with many competitors having greater financial and technical resources[113]. - The competitive landscape includes companies with greater financial and technical resources, which may hinder the Company's ability to keep pace in product development and market presence[165]. - The company competes against larger, well-capitalized food and ingredients companies, limiting its success in brand awareness[196]. Product Development and Market Challenges - The company’s future revenue depends on the success of its technologies and product developments, including extrusion, fermentation, and molecular farming[111]. - The introduction and improvement of new products from the Company's development pipeline are critical for generating revenue and achieving market acceptance[169]. - Significant risks in product development include delays in market acceptance, regulatory approvals, and competition from superior products[172]. - The company faces challenges in scaling agricultural production due to climatic variability, cost overruns, and low farmer adoption of target crops[173]. - The potential size of target markets for products is significant, but estimates are based on unverified assumptions that may not prove accurate[175]. - Negative public perception of GMOs and molecular farming could adversely affect commercialization efforts and regulatory environments[177][180]. - Consumer preferences for plant-based proteins are difficult to predict, and shifts away from the company's products could harm sales and market share[181][183]. Regulatory and Compliance Issues - The company’s operations are subject to various risks, including regulatory changes and compliance with environmental laws[115]. - The company is subject to numerous laws and regulations, including data protection and anti-corruption laws, which could result in liability if not complied with[200][201]. - Regulatory changes in the U.S. and abroad could increase the time and costs associated with launching new products, adversely affecting operating results[254]. - The regulatory environment outside the U.S. is highly uncertain, which may limit the company's ability to expand into global markets[255]. - Compliance with environmental, health, and safety regulations could be costly and time-consuming, potentially impairing research and development efforts[260]. Intellectual Property and Legal Risks - The company relies on a combination of intellectual property protections, but these may not be sufficient to prevent disclosure or infringement[234]. - License agreements with third parties limit the company's rights to use certain important technologies, and termination of these agreements could adversely affect operations[238]. - The company faces significant risks related to its patent positions, which may adversely affect its competitive position due to the complexity and uncertainty of biotechnology patents[240]. - The company may not be able to adequately enforce its intellectual property rights in jurisdictions where it has sought protection, potentially limiting its commercial success[241]. - Changes in patent laws could allow others to use the company's discoveries without compensation, impacting its ability to secure patent protection[243]. - The company may incur substantial costs in enforcing its patent rights, which could divert resources from other business areas and affect its operations[244]. Market and Economic Conditions - Economic instability in Argentina, including high inflation and currency fluctuations, poses material risks to the company's financial condition[208]. - The recent presidential elections in Argentina resulted in a new government that may introduce significant economic changes affecting the company[210]. - The ambitious deregulation plan under Decree 70/2023 and the Bases Law could significantly affect the company's business and financial condition[217]. - The agricultural industry is susceptible to commodity price changes, which may negatively impact the company's ability to commercialize products[226]. - The company's operations may be adversely affected by climate change and adverse weather conditions, which can reduce crop size and quality[229]. - The company's sales and operating results are highly seasonal, influenced by planting and harvest seasons, leading to substantial fluctuations[230]. Corporate Governance and Compliance with Nasdaq - The company is currently listed on the Nasdaq Capital Market and faces substantial doubt about its ability to comply with continued listing standards, which require a minimum of $500,000 in net income from continuing operations or at least $2.5 million in stockholders' equity[277]. - The company's ordinary shares have been trading below the minimum requirement of $1.00 per share for 30 consecutive business days, which could lead to automatic delisting from Nasdaq[280]. - On November 14, 2025, the company received a determination letter from Nasdaq regarding its non-compliance with the minimum bid price requirement[281]. - The company has submitted an appeal to request a 180-day period to submit a compliance plan, which may include a reverse stock split[282]. - A reverse stock split with a ratio of fifteen-to-one has been approved by the board, expected to be effective around January 5, 2026, to increase the ordinary share price[284]. - The company has not filed its Annual Report on Form 20-F for the year ended June 30, 2025, leading to a compliance issue with Nasdaq Listing Rule 5250(c)(1)[287]. - The complexities arising from the business combination in mid-June 2025 have delayed the filing of the Form 20-F[288]. - The company is committed to monitoring the closing bid price of its ordinary shares and evaluating actions to regain compliance with Nasdaq listing rules[285]. - If the ordinary shares are delisted, they may trade in the over-the-counter market, which could significantly affect liquidity and market perception[290]. Operational and Management Challenges - The company faces difficulties in integrating acquired businesses and realizing anticipated cost savings and synergies[118]. - The reliance on third-party growers for seed production poses risks to the Company's supply chain and operational stability[163]. - Attracting and retaining qualified employees is critical for the company's growth and operational success[188]. - The company faces potential substantial damages from defective product lawsuits, which may not be covered by insurance[193]. - Limited brand awareness could hinder the company's ability to sell products effectively[194]. - Significant resources will be required for a marketing campaign to improve brand awareness and market position[195]. - Failure to develop technology and brand could adversely affect future growth and customer loyalty[197]. - The company is increasingly reliant on third-party information technology systems, exposing it to operational risks and potential cyber-attacks[198]. - The resignation of Nomura as the exclusive financial advisor may indicate reluctance to be associated with the company's disclosures and business analysis[274]. - The trading volume and price of Ordinary Shares could decline if analysts cease coverage or change their recommendations adversely[299].